Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
2(40.0%)
5Total
Phase 2(3)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT00037609Phase 1Completed

Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients

Role: collaborator

NCT00036075Phase 2Completed

Study Using CP-461 to Treat Advanced Prostate Cancer

Role: collaborator

NCT00042055Phase 2Completed

CP-461 for the Treatment of Crohn's Disease

Role: collaborator

NCT00060710Phase 2Terminated

CP-461 in the Treatment of Patients With Advanced Melanoma

Role: collaborator

NCT00036257Phase 1Completed

Dose-Escalating and Safety Study of CP-461 in Patients With Chronic Lymphocytic Leukemia

Role: collaborator

All 5 trials loaded